Our goal in treating patients with glaucoma is to preserve their visual acuity to the greatest extent possible. Historically, however, we have avoided discussing refractive correction with them and thus ignored a salient fact: our patients want to see well. They are excited about successful cataract surgery, not about achieving a decrease in their IOP. Despite little hard data on how to approach refractive correction in these individuals, the topic is worthy of discussion.

**WHAT DO WE MEAN BY REFRACTIVE CORRECTION?**

Refractive correction includes a wide range of treatment options. It is as commonplace as a prescription for glasses or contact lenses. It may also take the form of cataract surgery or refractive lens exchange with the implantation of a monofocal lens, a phakic IOL, an aspheric lens, or one of the new accommodating or multifocal IOLs. Additional surgical options include conductive keratoplasty, LASIK, Epi-LASIK, and PRK.

**BENEFITS**

The advantage of refractive correction is obvious: sharper vision. Although many glaucoma patients will be satisfied with spectacles or contact lenses, a lot of them wish for the clearer visual acuity that only surgical intervention can achieve. Moreover, certain occupations (eg, airline pilot) require better visual acuity than is possible with glasses or contact lenses in some cases.

Highly myopic patients with glaucoma who undergo cataract surgery or refractive lens exchange often have residual sphere or astigmatism postoperatively. LASIK may be an appropriate means of fine-tuning their visual outcome. Additionally, removing the crystalline lens from moderately-to-highly hyperopic eyes during cataract surgery or refractive lens exchange could actually help avoid angle-closure glaucoma as well as control IOP.

Perhaps most important to consider is that, by discussing refractive correction with our patients, we are ensuring that they receive well-informed counsel about its compatibility with the management strategies for their glaucoma. Physicians who do not perform certain refractive procedures themselves can consider partnering with a refractive surgeon who will refer the patient back to them for continued management.

**CONCERNS**

Certainly, due to the risk of infection, contact lenses are not the best choice in patients who will soon undergo filtration surgery or who have a functioning bleb. The risk of an infected bleb, dysesthesia, and other ocular problems in patients wearing contact lenses after trabeculectomy warrants a discussion of alternative forms of refractive correction, including spectacles, excimer laser treatment, and cataract surgery. Of course, any surgical intervention also carries risks.

A possible objection to refractive surgery involving excimer laser ablation is that such procedures make interpreting the correct IOP challenging. Alternative devices such as the Pascal Dynamic Contour Tonometer (SMT Swiss Microtechnology AG, Port, Switzerland) do not solve the problem. The management of glaucoma...
involves more than simply monitoring IOP, however. We also track the appearance of the optic nerve and perform visual field testing, neither of which is affected by laser ablation. Before and after refractive surgery, it is essential that patients with glaucoma undergo baseline visual field testing and imaging of their optic nerves. The new baseline is important for clinical follow-up. In certain circumstances, it can address the question of whether the refractive procedure contributed to visual loss.

CONCLUSION

To avoid the subject of refractive correction in patients with glaucoma is to ignore reality. Instead, we should recognize that they want to see well and take a proactive approach regarding their visual acuity. In doing so, we are ensuring the oversight of their total vision care by physicians well versed in glaucoma management, including establishing a new baseline IOP, visual field testing, and the assessment of the optic disc. Most important, however, is that these patients maintain a continuity of follow-up, something that may be lost in a busy refractive surgery practice.

Richard A. Lewis, MD, is in private practice in Sacramento, California. He acknowledged no financial interest in the product or company mentioned herein. Dr. Lewis may be reached at (916) 649-1515; rlewisymd@yahoo.com.

SHARE YOUR FEEDBACK

Do you have an idea to share? Would you like to comment on a particular article or on Glaucoma Today as a whole? Send your remarks to us at gtlatters@bmctoday.com.

ISTALOL® (timolol maleate ophthalmic solution) 0.2%

Brief Summary of Prescribing Information

INDICATIONS AND USES

ISTALOL® ophthalmic solution is a diluent in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

CONTRAINdications

ISTALOL® is contraindicated in patients with (1) known sensitivity to timolol, (2) a history of bronchial asthma, (3) known chronic obstructive pulmonary disease (see DRUG INTERACTIONS), (4) sinus bradycardia, (5) second or third degree atrioventricular block, (6) overt congestive heart failure, (7) severe chronic bronchitis, (8) hypotension or (9) in any other condition in which its use is contraindicated or may be harmful to the patient.

WARNING

As with any topically applied ophthalmic drugs, this drug is a potential systemic. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions and cardiac reactions, usually associated with beta-blockers used in the treatment of asthma, and rarely death in association with cardiac failure, have been reported following systemic administration of timolol maleate (see CONTRAINDICATIONS).

Conjunctival Herbaceous papillae: Intracameral injection of betaxolol hydrochloride may result in an increase in the number of conjunctival papillae.

Patients with a history of bronchial asthma, chronic obstructive pulmonary disease and/or chronic bronchitis, emphysema of mild to moderate severity, bronchospastic disease, or a history of bronchospastic disease, other than as a complication of asthma or a history of bronchial asthma, in which ISTALOL® is contraindicated (see CONTRAINDICATIONS) should in general not receive beta-blockers, including ISTALOL®. Blinder, S. and Berg, S., (1969). The necessity or necessity of withdrawal of beta-adrenergic blocking agents prior to major surgery is controversial. Beta-adrenergic blocking agents have been shown to decrease the response to stress and to modify aspects of the patient’s stress response. Beta-blockers have been shown to decrease the incidence and severity of a variety of cardiac arrhythmias. Before and after refractive surgery, it is essential that patients with glaucoma undergo baseline visual field testing and imaging of their optic nerves. The new baseline is important for clinical follow-up. In certain circumstances, it can address the question of whether the refractive procedure contributed to visual loss.

CONCLUSION

To avoid the subject of refractive correction in patients with glaucoma is to ignore reality. Instead, we should recognize that they want to see well and take a proactive approach regarding their visual acuity. In doing so, we are ensuring the oversight of their total vision care by physicians well versed in glaucoma management, including establishing a new baseline IOP, visual field testing, and the assessment of the optic disc. Most important, however, is that these patients maintain a continuity of follow-up, something that may be lost in a busy refractive surgery practice.

Richard A. Lewis, MD, is in private practice in Sacramento, California. He acknowledged no financial interest in the product or company mentioned herein. Dr. Lewis may be reached at (916) 649-1515; rlewisyemd@yahoo.com.

SHARE YOUR FEEDBACK

Do you have an idea to share? Would you like to comment on a particular article or on Glaucoma Today as a whole? Send your remarks to us at gtlatters@bmctoday.com.

ISTALOL® (timolol maleate ophthalmic solution) 0.2%

Brief Summary of Prescribing Information

INDICATIONS AND USES

ISTALOL® ophthalmic solution is a diluent in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

CONTRAINdications

ISTALOL® is contraindicated in patients with (1) known sensitivity to timolol, (2) a history of bronchial asthma, (3) known chronic obstructive pulmonary disease (see DRUG INTERACTIONS), (4) sinus bradycardia, (5) second or third degree atrioventricular block, (6) overt congestive heart failure, (7) severe chronic bronchitis, (8) hypotension or (9) in any other condition in which its use is contraindicated or may be harmful to the patient.

WARNING

As with any topically applied ophthalmic drugs, this drug is a potential systemic. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions and cardiac reactions, usually associated with beta-blockers used in the treatment of asthma, and rarely death in association with cardiac failure, have been reported following systemic administration of timolol maleate (see CONTRAINDICATIONS).

Conjunctival Herbaceous papillae: Intracameral injection of betaxolol hydrochloride may result in an increase in the number of conjunctival papillae.

Patients with a history of bronchial asthma, chronic obstructive pulmonary disease and/or chronic bronchitis, emphysema of mild to moderate severity, bronchospastic disease, or a history of bronchospastic disease, other than as a complication of asthma or a history of bronchial asthma, in which ISTALOL® is contraindicated (see CONTRAINDICATIONS) should in general not receive beta-blockers, including ISTALOL®.

Blinder, S. and Berg, S., (1969). The necessity or necessity of withdrawal of beta-adrenergic blocking agents prior to major surgery is controversial. Beta-adrenergic blocking agents have been shown to decrease the response to stress and to modify aspects of the patient’s stress response. Beta-blockers have been shown to decrease the incidence and severity of a variety of cardiac arrhythmias.

Before and after refractive surgery, it is essential that patients with glaucoma undergo baseline visual field testing and imaging of their optic nerves. The new baseline is important for clinical follow-up. In certain circumstances, it can address the question of whether the refractive procedure contributed to visual loss.

CONCLUSION

To avoid the subject of refractive correction in patients with glaucoma is to ignore reality. Instead, we should recognize that they want to see well and take a proactive approach regarding their visual acuity. In doing so, we are ensuring the oversight of their total vision care by physicians well versed in glaucoma management, including establishing a new baseline IOP, visual field testing, and the assessment of the optic disc. Most important, however, is that these patients maintain a continuity of follow-up, something that may be lost in a busy refractive surgery practice.

Richard A. Lewis, MD, is in private practice in Sacramento, California. He acknowledged no financial interest in the product or company mentioned herein. Dr. Lewis may be reached at (916) 649-1515; rlewisyemd@yahoo.com.

SHARE YOUR FEEDBACK

Do you have an idea to share? Would you like to comment on a particular article or on Glaucoma Today as a whole? Send your remarks to us at gtlatters@bmctoday.com.